Raxone
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Idebenone
- Made by
- Chiesi Farmaceutici S.p.A
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Chiesi Farmaceutici S.p.A |
|---|---|
| Active substance | Idebenone |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N06BX13 · Pain, sleep, mood, epilepsy and the brain |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2015-09-08 |
| Last updated by the regulator | 2025-08-20 |
| EMA product number | EMEA/H/C/003834 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).